China’s Center for Drug Evaluation of the National Medical Products Administration has recently approved a Phase-I clinical trial for a new mRNA tumor vaccine targeting Epstein-Barr virus (EBV) positive tumors. Developed independently by WestGene Biopharma, a Chengdu-based company, this vaccine represents a significant advancement in the field of tumor immunotherapy. Earlier this year, the mRNA...
